Friday, November 11, 2016 5:27:18 PM
B...with predictions like this ....
youre at risk of losing your followers.
better slow down a little....
study the charts more....
AVXL is gently testing the 3.25/3.35 resistance zone, and staying snug in between the 3.15 "support" step. more waiting.
Junior Biotech sector did well this week,but its in danger territory.
Heres the big picture for XBI since the 2008 crash.
The normal Fibonacci target zone for the whole rally was at the 60 area...the rest of the bubble surge for 2015 was a new cycle,that has peak targets around 130.(and now another math target around 115 if we do get a great rally developing)
But why then did it stop at 90 and make this giant 50% haircut to 44? it would suggest the 90 peak was a finished rally. From there comes the pullback/downwave a 50% haircut to 44, but now this 2016 bounce is reaching resistance areas. its dangerous for rollover here around 66-70,despite this week's big bounce. I suspect the XBI could roll over heading into 2017 and retest the 35 area.
This chart ,the giant rally from 2008 bottom, "should have" ended in 2014 at the 60 area. the pullback to 37 was ok. but the peak at 90 ,IF it was a "wave 3" peak , should have held a much more shallow pullback,closer to the 75 area.This giant haircut to 44,acted like a 'wave 2' ,so either the XBI will make another giant rally in 2017 to target 115/130 area or it will make another big downwave to retest 30/37 area. Here at the 70 area is a dangerous middle zone that could be propelled in either direction.
Does Trump like the biotech sector? He said comments about the FDA holding up drugs that can help people. But politicians will say everything the public needs to hear, and then they do what the Big Pharma powers tell them to do. Trump wont be allowed to take charge like he's the boss of America now. He's a puppet who will do what is expected of him.
IF the biotech sector rallies higher it wont be because of Trump, it will be because the Wall street powers want to make more profits before they crash the whole market.
So,maybe we will see another rally in Biotech, but folks better be nimble to take profits and get out before the next Crash comes.
youre at risk of losing your followers.
better slow down a little....
study the charts more....
AVXL is gently testing the 3.25/3.35 resistance zone, and staying snug in between the 3.15 "support" step. more waiting.
Junior Biotech sector did well this week,but its in danger territory.
Heres the big picture for XBI since the 2008 crash.
The normal Fibonacci target zone for the whole rally was at the 60 area...the rest of the bubble surge for 2015 was a new cycle,that has peak targets around 130.(and now another math target around 115 if we do get a great rally developing)
But why then did it stop at 90 and make this giant 50% haircut to 44? it would suggest the 90 peak was a finished rally. From there comes the pullback/downwave a 50% haircut to 44, but now this 2016 bounce is reaching resistance areas. its dangerous for rollover here around 66-70,despite this week's big bounce. I suspect the XBI could roll over heading into 2017 and retest the 35 area.
This chart ,the giant rally from 2008 bottom, "should have" ended in 2014 at the 60 area. the pullback to 37 was ok. but the peak at 90 ,IF it was a "wave 3" peak , should have held a much more shallow pullback,closer to the 75 area.This giant haircut to 44,acted like a 'wave 2' ,so either the XBI will make another giant rally in 2017 to target 115/130 area or it will make another big downwave to retest 30/37 area. Here at the 70 area is a dangerous middle zone that could be propelled in either direction.
Does Trump like the biotech sector? He said comments about the FDA holding up drugs that can help people. But politicians will say everything the public needs to hear, and then they do what the Big Pharma powers tell them to do. Trump wont be allowed to take charge like he's the boss of America now. He's a puppet who will do what is expected of him.
IF the biotech sector rallies higher it wont be because of Trump, it will be because the Wall street powers want to make more profits before they crash the whole market.
So,maybe we will see another rally in Biotech, but folks better be nimble to take profits and get out before the next Crash comes.
Recent AVXL News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
